<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vmireaviz</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник медицинского института «РЕАВИЗ». Реабилитация, Врач и Здоровье</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-762X</issn><issn pub-type="epub">2782-1579</issn><publisher><publisher-name>РЕАВИЗ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20340/vmi-rvz.2023.3.COVID.2</article-id><article-id custom-type="elpub" pub-id-type="custom">vmireaviz-778</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Новая коронавирусная инфекция COVID-19</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Novel coronavirus infection COVID-19</subject></subj-group></article-categories><title-group><article-title>Отдельные аспекты специфической профилактики новой коронавирусной инфекции, вызванной вирусом SARS CoV-2, в Самарской области</article-title><trans-title-group xml:lang="en"><trans-title>Some aspects of specific prevention of a new coronavirus infection caused by the SARS CoV-2 virus in the Samara region</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-4682-3880</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кирюхин</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kiryukhin</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кирюхин Антон Игоревич, ассистент кафедры инфекционных болезней с эпидемиологией</p><p>ул. Чапаевская, д. 89, Самара, 443099</p></bio><bio xml:lang="en"><p>Anton I. Kiryukhin, Assistant of the Department of Infectious Diseases with Epidemiology</p><p>89 Chapaevskaya str., Samara, 443099</p></bio><email xlink:type="simple">a.i.kiryuhin@samsmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4283-1481</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Темник</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Temnik</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Темник Елизавета Игоревна, ассистент кафедры инфекционных болезней с эпидемиологией</p><p>ул. Чапаевская, д. 89, Самара, 443099</p></bio><bio xml:lang="en"><p>Elizaveta I.Temnik, Assistant of the Department of Infectious Diseases with Epidemiology</p><p>89 Chapaevskaya str., Samara, 443099</p></bio><email xlink:type="simple">elizabeth_temnik@outlook.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0549-361X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попова</surname><given-names>Л. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Popova</surname><given-names>L. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Попова Лариса Леонидовна, д-р мед. наук, профессор, профессор кафедры инфекционных болезней с эпидемиологией</p><p>ул. Чапаевская, д. 89, Самара, 443099</p></bio><bio xml:lang="en"><p>Larisa L. Popova, Dr. Sci. (Med.), Professor, Professor of the Department of Infectious Diseases with Epidemiology</p><p>89 Chapaevskaya str., Samara, 443099</p></bio><email xlink:type="simple">l.l.popova@samsmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6177-8487</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Константинов</surname><given-names>Д. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Konstantinov</surname><given-names>D. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Константинов Дмитрий Юрьевич, д-р мед. наук, доцент, заведующий кафедрой инфекционных болезней с эпидемиологией</p><p>ул. Чапаевская, д. 89, Самара, 443099</p></bio><bio xml:lang="en"><p>Dmitry Y. Konstantinov, Dr. Sci. (Med.), Docent, Head of the Department of Infectious Diseases with Epidemiology</p><p>89 Chapaevskaya str., Samara, 443099</p></bio><email xlink:type="simple">d.u.konstantinov@samsmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Самарский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Samara State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>20</day><month>06</month><year>2023</year></pub-date><volume>13</volume><issue>3</issue><fpage>18</fpage><lpage>23</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кирюхин А.И., Темник Е.И., Попова Л.Л., Константинов Д.Ю., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Кирюхин А.И., Темник Е.И., Попова Л.Л., Константинов Д.Ю.</copyright-holder><copyright-holder xml:lang="en">Kiryukhin A.I., Temnik E.I., Popova L.L., Konstantinov D.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vestnik.reaviz.ru/jour/article/view/778">https://vestnik.reaviz.ru/jour/article/view/778</self-uri><abstract><p>Новая коронавирусная инфекция остаётся значимым медико-социальным событием в мире, и только активная иммунизация населения с достижением целевого уровня охвата вакцинацией не менее 60 % способна остановить её распространение.</p><sec><title>Цель</title><p>Цель: оценить предварительные итоги вакцинации против новой коронавирусной инфекции, вызванной вирусом SARS CoV-2, в Самарской области.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Материалом настоящего исследования явились результаты статистического мониторинга заболеваемости новой коронавирусной инфекцией, вызванной вирусом SARS CoV-2, у жителей Самарской области и данные о прививочной кампании. Статистический анализ включил дескриптивное, сравнительное и интервальное оценивание, а также корреляционный анализ.</p></sec><sec><title>Результаты</title><p>Результаты. По состоянию на октябрь 2022 г. вакцинировано против новой коронавирусной инфекции, вызванной вирусом SARS CoV-2, 62,6 % всего населения Самарской области. Среди привитых преобладали женщины – 60,51 %. При анализе результатов прививочной кампании выявлены статистически значимые отрицательные взаимосвязи между долей вакцинированных в определённый месяц и заболеваемостью в последующие три месяца, а также между накопленным процентом вакцинированных и заболеваемостью в ближайшие несколько месяцев. При этом, заболеваемость и вакцинированность в нормированном на численность населения виде не зависит от величины численности.</p></sec><sec><title>Выводы</title><p>Выводы. По данным в Самарской области вакцинация снижает риск заболевания новой коронавирусной инфекцией, вызванной вирусом SARS CoV-2, в среднем в 7,4 раза. При развитии манифестной формы новой коронавирусной инфекции, вызванной вирусом SARS CoV-2, у жителей Самарской области, прошедших полный курс вакцинации, риск развития тяжёлой и крайне тяжёлой формы снижается в среднем в 1,65 раза, а летальных исходов – в 1,71 раза. </p></sec></abstract><trans-abstract xml:lang="en"><p>The new coronavirus infection remains a significant medical and social event in the world, and only active immunization of the population with the achievement of the target level of vaccination coverage of at least 60% is able to stop its spread.</p><sec><title>Objective</title><p>Objective: to study the preliminary results of vaccination against a new coronavirus infection caused by the SARS CoV-2 virus in the Samara region.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The material of this study was the results of statistical monitoring of the incidence of a new coronavirus infection caused by the SARS CoV-2 virus in residents of the Samara region and data on the vaccination campaign. Statistical analysis included descriptive, comparative and interval estimation, as well as correlation analysis.</p></sec><sec><title>Results</title><p>Results. As of October 2022, 62.6% of the total population in the Samara region has been vaccinated against a new coronavirus infection caused by the SARS CoV-2 virus. Women predominated among those vaccinated – 60.51%. When analyzing the results of the vaccination campaign, statistically significant negative relationships were revealed between the proportion of vaccinated in a certain month and the incidence in the next three months, as well as between the accumulated percentage of vaccinated and the incidence in the next few months. At the same time, morbidity and vaccination in a normalized form for the population does not depend on the size of the population.</p></sec><sec><title>Conclusions</title><p>Conclusions: Vaccination reduces the risk of a new coronavirus infection caused by the SARS CoV-2 virus in the Samara region by an average of 7.4 times. With the development of a manifest form of a new coronavirus infection caused by the SARS CoV-2 virus, in residents of the Samara region who have undergone a full course of vaccination, the risk of developing severe and extremely severe forms decreases by an average of 1.65 times, and deaths – by 1.71 times.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>коронавирусная инфекция</kwd><kwd>SARS CoV-2</kwd><kwd>COVID-19</kwd><kwd>Самарская область</kwd><kwd>вакцинация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>coronavirus infection</kwd><kwd>SARS CoV-2</kwd><kwd>COVID-19</kwd><kwd>Samara region</kwd><kwd>vaccination</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование проводилось без спонсорской поддержки.</funding-statement><funding-statement xml:lang="en">This research received no external funding.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Временные рекомендации ВОЗ «Принципы реализации и корректировки мер по защите здоровья населения и социальных мер в связи с распространением COVID-19» 14 июня 2021 г. https://apps.who.int/iris/bitstream/handle/10665/341811/WHO-2019-nCoV-Adjusting-PH-measures-2021.1-rus.pdf</mixed-citation><mixed-citation xml:lang="en">WHO Interim Recommendations "Principles of implementation and adjustment of measures to protect public health and social measures in connection with the spread of COVID-19" June 14, 2021. (In Russ). https://apps.who.int/iris/bitstream/handle/10665/341811/WHO-2019-nCoV-Adjusting-PH-measures-2021.1-rus.pdf</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Khan S., Ali A., Siddique R., Nabi G. Novel coronavirus is putting the whole world on alert. J Hosp Infect. 2020 Mar;104(3):252–253. https://doi.org/10.1016/j.jhin.2020.01.019</mixed-citation><mixed-citation xml:lang="en">Khan S., Ali A., Siddique R., Nabi G. Novel coronavirus is putting the whole world on alert. J Hosp Infect. 2020 Mar;104(3):252–253. https://doi.org/10.1016/j.jhin.2020.01.019</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yu Shi, Gang Wang, Xiao-peng Cai, Jing-wen Deng, Lin Zheng, et al. An overview of COVID-19. Journal of Zhejiang University SCIENCE B. 2020;21(5):343–360. http://doi.org/10.1631/jzus.B2000083</mixed-citation><mixed-citation xml:lang="en">Yu Shi, Gang Wang, Xiao-peng Cai, Jing-wen Deng, Lin Zheng, et al. An overview of COVID-19. Journal of Zhejiang University SCIENCE B. 2020;21(5):343–360. http://doi.org/10.1631/jzus.B2000083</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Отчеты Коммуникационного центра Правительства РФ по ситуации с коронавирусом. https://стопкоронавирус.рф/info/ofdoc/reports/</mixed-citation><mixed-citation xml:lang="en">Reports of the Communication Center of the Government of the Russian Federation on the situation with coronavirus. (In Russ). https://стопкоронавирус.рф/info/ofdoc/reports/</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Отчеты Оперативного штаба Самарской области по ситуации с коронавирусом. https://www.samregion.ru/institutions/aktualnye-temy-dlya-grazhdan-regiona/stop_covid_2019/novosti/</mixed-citation><mixed-citation xml:lang="en">Reports of the Operational Headquarters of the Samara region on the situation with coronavirus. (In Russ). https://www.samregion.ru/institutions/aktualnye-temy-dlya-grazhdan-regiona/stop_covid_2019/novosti/</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sana O Alturki, Sawsan O Alturki, Jennifer Connors, Gina Cusimano, Michele A Kutzler, Abdullah M Izmirly et al. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. Front Immunol. 08,2020;11:1880; PMID: 32973779. http://doi.org/10.3389/fimmu.2020.01880</mixed-citation><mixed-citation xml:lang="en">Sana O Alturki, Sawsan O Alturki, Jennifer Connors, Gina Cusimano, Michele A Kutzler, Abdullah M Izmirly et al. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. Front Immunol. 08,2020;11:1880; PMID: 32973779. http://doi.org/10.3389/fimmu.2020.01880</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Doroftei Bogdan, Ciobica Alin, Ilie Ovidiu-Dumitru, Maftei Radu and Ilea Ciprian. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics. 2021;11(4):579. https://doi.org/10.3390/diagnostics11040579</mixed-citation><mixed-citation xml:lang="en">Doroftei Bogdan, Ciobica Alin, Ilie Ovidiu-Dumitru, Maftei Radu and Ilea Ciprian. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics. 2021;11(4):579. https://doi.org/10.3390/diagnostics11040579</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Logunov Denis Y, Dolzhikova Inna V, Shcheblyakov Dmitry V, Tukhvatulin Amir I, Zubkova Olga V, Dzharullaeva Alina S et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 02, 2021;397:671–681. https://doi.org/10.1016/S0140-6736(21)00234-8</mixed-citation><mixed-citation xml:lang="en">Logunov Denis Y, Dolzhikova Inna V, Shcheblyakov Dmitry V, Tukhvatulin Amir I, Zubkova Olga V, Dzharullaeva Alina S et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 02, 2021;397:671–681. https://doi.org/10.1016/S0140-6736(21)00234-8</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Рыжиков А.Б., Рыжиков Е.А., Богрянцева М.П., Усова С.В., Даниленко Е.Д., Нечаева Е.А. и др. Простое слепое плацебо-контролируемое рандомизированное исследование безопасности, реактогенности и иммуногенности вакцины «ЭпиВакКорона» для профилактики COVID-19 на добровольцах в возрасте 18–60 лет (фаза I–II). Инфекция и иммунитет. 2021;11(2):283–296. https://doi.org/10.15789/2220-7619-ASB-1699</mixed-citation><mixed-citation xml:lang="en">Ryzhikov A.B., Ryzhikov E.A., Bagryantseva M.P., Usova S.V., Danilenko E.D., Nechaeva E.A., etc. A simple blind placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the EpiVacCorona vaccine for the prevention of COVID-19 on volunteers aged 18-60 years (phase I–II). Infection and immunity. 2021;11(2):283–296. (In Russ). https://doi.org/10.15789/2220-7619-ASB-1699</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Козловская Л.И., Пиниева А.Н., Игнатьев Г.М., Гордейчук И.В., Волок В.П., Рогова Ю.В. и др. Долгосрочная гуморальная иммуногенность, безопасность и защитная эффективность инактивированной вакцины против COVID-19 (CoviVac) в доклинических исследованиях. Новые микробы и инфекции. 2021;10(1):1790–1806. https://www.tandfonline.com/doi/full/10.1080/22221751.2021.1971569</mixed-citation><mixed-citation xml:lang="en">Kozlovskaya L.I., Pinaeva A.N., Ignatiev G.M., Gordeychuk I.V., Volok V.P., Rogova Yu.V., etc. Long-term humoral immunogenicity, safety and protective efficacy of inactivated COVID-19 vaccine (CoviVac) in preclinical studies. New germs and infections. 2021;10(1):1790–1806. (In Russ). https://www.tandfonline.com/doi/full/10.1080/22221751.2021.1971569</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Stephen J. Thomas, Edson D. Moreira, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385:1761–1773. https://doi.org/10.1056/NEJMoa2110345</mixed-citation><mixed-citation xml:lang="en">Stephen J. Thomas, Edson D. Moreira, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385:1761–1773. https://doi.org/10.1056/NEJMoa2110345</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Katherine R W Emary, Tanya Golubchik, Parvinder K Aley, Cristina V Ariani, Brian Angus, Sagida Bibi et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351–1362.https://doi.org/10.1016/S0140-6736(21)00628-0</mixed-citation><mixed-citation xml:lang="en">Katherine R W Emary, Tanya Golubchik, Parvinder K Aley, Cristina V Ariani, Brian Angus, Sagida Bibi et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351–1362.https://doi.org/10.1016/S0140-6736(21)00628-0</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Paul T. Heath, Eva P. Galiza, David N. Baxter, Marta Boffito, Duncan Browne, Fiona Burns et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021;385:1172–1183. https://doi.org/10.1056/NEJMoa2107659</mixed-citation><mixed-citation xml:lang="en">Paul T. Heath, Eva P. Galiza, David N. Baxter, Marta Boffito, Duncan Browne, Fiona Burns et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021;385:1172–1183. https://doi.org/10.1056/NEJMoa2107659</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Jerald Sadoff, Glenda Gray, An Vandebosch, Vicky Cárdenas, Georgi Shukarev, Beatriz Grinsztejn et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384:2187–2201. https://doi.org/10.1056/NEJMoa2101544</mixed-citation><mixed-citation xml:lang="en">Jerald Sadoff, Glenda Gray, An Vandebosch, Vicky Cárdenas, Georgi Shukarev, Beatriz Grinsztejn et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384:2187–2201. https://doi.org/10.1056/NEJMoa2101544</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Nawal Al Kaabi, Yuntao Zhang, Shengli Xia et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. A Randomized Clinical Trial. JamaNetwork. 2021;May 12. https://doi.org/10.1001/jama.2021.8565</mixed-citation><mixed-citation xml:lang="en">Nawal Al Kaabi, Yuntao Zhang, Shengli Xia et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. A Randomized Clinical Trial. JamaNetwork. 2021;May 12. https://doi.org/10.1001/jama.2021.8565</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Susan M Bueno, Katia Abarca, Pablo A González, Nicolás Ms Gálvez, Jorge A Soto, Luisa F Duarte et al. Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. MedRxiv. 2021 Apr 1;2021.03.31.21254494; PMID: 35441164; https://doi.org/10.1101/2021.03.31.21254494</mixed-citation><mixed-citation xml:lang="en">Susan M Bueno, Katia Abarca, Pablo A González, Nicolás Ms Gálvez, Jorge A Soto, Luisa F Duarte et al. Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. MedRxiv. 2021 Apr 1;2021.03.31.21254494; PMID: 35441164; https://doi.org/10.1101/2021.03.31.21254494</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Билёв А.Е., Сокурова А.М., Билёва Н.А., Качковский М.А., Введенская И.П. Российские вакцины против COVID-19: их характеристики, эффективность и безопасность. Вестник медицинского института «РЕАВИЗ». Реабилитация, Врач и Здоровье. 2022;12(6):6-14. https://doi.org/10.20340/vmi-rvz.2022.6.COVID.1)</mixed-citation><mixed-citation xml:lang="en">Bilev A.E., Sokurova A.M., Bileva N.A., Kachkovskii M.A., Vvedenskaya I.P. Russian vaccines against COVID-19: their characteristics, efficacy and safety. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2022;12(6):6-14. (In Russ). https://doi.org/10.20340/vmi-rvz.2022.6.COVID.1]</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Karen Kotloff, Sharon Frey, Rick Novak et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–416. https://doi.org/10.1056/NEJMoa2035389</mixed-citation><mixed-citation xml:lang="en">Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Karen Kotloff, Sharon Frey, Rick Novak et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–416. https://doi.org/10.1056/NEJMoa2035389</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) версия 16 (18.08.2022). https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/060/193/original/ВМР_COVID-19_V16.pdf</mixed-citation><mixed-citation xml:lang="en">Temporary guidelines: prevention, diagnosis and treatment of new coronavirus infection (COVID-19) version 16 (08/18/2022). (In Russ). https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/060/193/original/ВМР_COVID-19_V16.pdf</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
